

**Original images of all blot results reported in the main article and
the supplementary materials of**

**“Differential effects of oligosaccharides, antioxidants, amino acids and
PUFAs on heat/hypoxia-induced epithelial injury in a Caco-2/HT-29
co-culture model”**

Puqiao Lian¹, Paul A. J. Henricks¹, Harry J. Wichers², Gert Folkerts¹, Saskia Braber¹

¹ Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science,
Utrecht University, Utrecht, The Netherlands

² Food & Biobased Research, Wageningen University, Wageningen, the Netherlands

Corresponding author:

S. Braber


Utrecht University, Department of Pharmaceutical Sciences, Division of Pharmacology

Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands


Telephone: +31 302531599

Email: s.braber@uu.nl

Original blot images supporting Figure 4:




Repeat 1 of ZO-1, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.



Repeat 1 of ZO-1, upper lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M; lower lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of ZO-1, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of ZO-1, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M;




Repeat 2 of ZO-1, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.



Repeat 3 of ZO-1, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.



Repeat 3 of ZO-1, upper lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M; lower lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M




Repeat 1 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 1 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 1 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 2 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 3 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 3 of β -actin, upper lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M; lower lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.


Original blot images supporting Figure 5:




Repeat 1 of CLDN3, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 1 of CLDN3, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 1 of CLDN3, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of CLDN3, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of CLDN3, lanes from left to right: Control, Model, RES 25, 50, 100 µM, ALA 25, 50, 100 µM.




Repeat 2 of CLDN3, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 µM.




Repeat 3 of CLDN3, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 3 of CLDN3, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 3 of CLDN3, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.



Repeat 1 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 1 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 1 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 2 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 3 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 3 of β -actin, upper lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M; lower lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.

Original blot images supporting Figure 7:




Repeat 1 of HSP-70, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.



Repeat 1 of HSP-70, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 1 of HSP-70, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of HSP-70, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of HSP-70, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 2 of HSP-70, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 3 of HSP-70, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.



Repeat 3 of HSP-70, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 3 of HSP-70, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.



Repeat 1 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 1 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 1 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 2 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 3 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.



Repeat 3 of β -actin, upper lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M; lower lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.


Original blot images supporting Figure S3:




Repeat 1 of HIF-1 α , lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 1 of HIF-1 α , lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 1 of HIF-1 α , lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of HIF-1 α , lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of HIF-1 α , lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 2 of HIF-1 α , lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 3 of HIF-1 α , lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 3 of HIF-1 α , lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 3 of HIF-1 α , lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 1 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 1 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.




Repeat 1 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.




Repeat 2 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.




Repeat 2 of β -actin, lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M.



Repeat 2 of β -actin, lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.



Repeat 3 of β -actin, lanes from left to right: Control, Model, GOS 2.5, 5, 10 mg/ml, FOS 5, 10, 20 mg/ml, COS 2.5, 5, 10 mg/ml.



Repeat 3 of β -actin, upper lanes from left to right: Control, Model, RES 25, 50, 100 μ M, ALA 25, 50, 100 μ M; lower lanes from left to right: Control, Model, Arg 0.5, 1.0, 2.0 mM, EPA 12.5, 25, 50 μ M.